Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.

Szczegóły
Abstrakt

Tytuł:: Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.
Autorzy:: Tamura K; Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA.
Wakimoto H
Agarwal AS
Rabkin SD
Bhere D
Martuza RL
Kuroda T
Kasmieh R
Shah K
Źródło:: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2013 Jan; Vol. 21 (1), pp. 68-77. Date of Electronic Publication: 2012 Aug 28.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: 2017- : Cambridge, MA : Cell Press
Original Publication: San Diego, CA : Academic Press, 2000-
MeSH Terms:: Drug Resistance, Neoplasm*
Oncolytic Virotherapy*
Brain Neoplasms/*therapy
Glioblastoma/*therapy
Neoplastic Stem Cells/*pathology
Animals ; Apoptosis ; Brain Neoplasms/pathology ; Cell Line, Tumor ; Glioblastoma/pathology ; Humans ; MAP Kinase Signaling System ; Mice ; Neoplasm Invasiveness ; TNF-Related Apoptosis-Inducing Ligand/metabolism
References:: Gene Ther. 2006 Dec;13(24):1731-6. (PMID: 16871231)
Nat Clin Pract Oncol. 2007 Feb;4(2):101-17. (PMID: 17259931)
Cell Death Differ. 2003 Jan;10(1):66-75. (PMID: 12655296)
Nat Med. 1995 Sep;1(9):938-43. (PMID: 7585221)
Cell Physiol Biochem. 2007;20(1-4):23-34. (PMID: 17595512)
Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895)
Mol Ther. 2005 Jun;11(6):926-31. (PMID: 15922963)
Cancer Res. 2007 Sep 15;67(18):8783-90. (PMID: 17875719)
Science. 1995 Nov 24;270(5240):1326-31. (PMID: 7481820)
Nat Cell Biol. 2003 Jul;5(7):647-54. (PMID: 12792650)
Mol Ther. 2009 Jan;17(1):199-207. (PMID: 18957964)
Neoplasia. 2007 May;9(5):435-42. (PMID: 17534449)
Cancer Res. 2011 Jan 1;71(1):154-63. (PMID: 21084267)
Genes Dev. 2004 Mar 15;18(6):660-72. (PMID: 15075293)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Cell. 1997 Feb 7;88(3):347-54. (PMID: 9039261)
Mol Cancer Ther. 2009 Jun;8(6):1515-25. (PMID: 19509255)
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401. (PMID: 11353831)
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7. (PMID: 19264968)
Hum Gene Ther. 1998 Dec 10;9(18):2787-94. (PMID: 9874276)
Gene Ther. 2000 May;7(10):867-74. (PMID: 10845725)
Cancer Gene Ther. 2007 Jul;14(7):627-39. (PMID: 17479104)
Oncogene. 2005 Nov 21;24(52):7802-16. (PMID: 16299539)
Mol Biol Cell. 2002 Feb;13(2):393-401. (PMID: 11854398)
Nature. 2011 Aug 31;477(7362):99-102. (PMID: 21886163)
Cell Cycle. 2009 Apr 15;8(8):1168-75. (PMID: 19282669)
Clin Cancer Res. 2010 Mar 15;16(6):1701-8. (PMID: 20197482)
Lancet Oncol. 2008 Apr;9(4):376-84. (PMID: 18374291)
EMBO J. 2000 Oct 16;19(20):5418-28. (PMID: 11032809)
Cancer Gene Ther. 2002 Dec;9(12):967-78. (PMID: 12522436)
Cell Adh Migr. 2008 Jul-Sep;2(3):208-13. (PMID: 19262110)
Cancer Res. 2007 Oct 1;67(19):8994-9000. (PMID: 17908999)
Nat Rev Cancer. 2005 Dec;5(12):965-76. (PMID: 16294217)
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9583-7. (PMID: 8790373)
Cancer Res. 2004 May 1;64(9):3236-42. (PMID: 15126365)
Nat Rev Cancer. 2008 Oct;8(10):782-98. (PMID: 18813321)
J Neurosci. 2008 Apr 23;28(17):4406-13. (PMID: 18434519)
J Gene Med. 2007 Feb;9(2):99-106. (PMID: 17256802)
Int J Hematol. 2009 Apr;89(3):294-297. (PMID: 19229589)
N Engl J Med. 2008 Jul 31;359(5):492-507. (PMID: 18669428)
J Neurovirol. 2003 Feb;9(1):101-11. (PMID: 12587073)
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7891-6. (PMID: 9223283)
Oncogene. 2003 Oct 9;22(44):6865-72. (PMID: 14534533)
Curr Opin Mol Ther. 2008 Aug;10(4):334-42. (PMID: 18683097)
Cancer Res. 2009 Apr 15;69(8):3472-81. (PMID: 19351838)
J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81. (PMID: 18042934)
Cancer Res. 2005 Dec 1;65(23):10663-8. (PMID: 16322208)
Mol Cell Biol. 1999 Aug;19(8):5308-15. (PMID: 10409722)
Nat Med. 2001 Jul;7(7):781-7. (PMID: 11433341)
BMC Biotechnol. 2006 Sep 22;6:40. (PMID: 16995942)
Grant Information:: NS03677 United States NS NINDS NIH HHS; R01 NS032677 United States NS NINDS NIH HHS; R01 CA138922 United States CA NCI NIH HHS; CA138922-01 United States CA NCI NIH HHS; NS076873 United States NS NINDS NIH HHS; R21 NS076873 United States NS NINDS NIH HHS
Substance Nomenclature:: 0 (TNF-Related Apoptosis-Inducing Ligand)
0 (TNFSF10 protein, human)
Entry Date(s):: Date Created: 20120830 Date Completed: 20130723 Latest Revision: 20211021
Update Code:: 20240104
PubMed Central ID:: PMC3538303
DOI:: 10.1038/mt.2012.175
PMID:: 22929661
: Czasopismo naukowe

Full Text Finder

Only a subset of cancer patients inoculated with oncolytic herpes simplex virus (oHSV) type-1 has shown objective response in phase 1 and 2 clinical trials. This has raised speculations whether resistance of tumor cells to oHSV therapy may be a limiting factor. In this study, we have identified established and patient derived primary glioblastoma multiforme (GBM) stem cell lines (GSC) resistant to oHSV and also to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that has recently shown promise in preclinical and initial clinical studies. We created a recombinant oHSV bearing a secretable TRAIL (oHSV-TRAIL) and hypothesized that oHSV-TRAIL could be used as a cancer therapeutic to target a broad spectrum of resistant tumors in a mechanism-based manner. Using the identified resistant GBM lines, we show that oHSV-TRAIL downregulates extracellular signal-regulated protein kinase (ERK)-mitogen-activated protein kinase (MAPK) and upregulates c-Jun N-terminal kinase (JNK) and p38-MAPK signaling, which primes resistant GBM cells to apoptosis via activation of caspase-8, -9, and -3. We further show that oHSV-TRAIL inhibits tumor growth and invasiveness and increases survival of mice bearing resistant intracerebral tumors without affecting the normal tissues. This study sheds new light on the mechanism by which oHSV and TRAIL function in concert to overcome therapeutic-resistance, and provides an oncolytic virus based platform to target a broad spectrum of different cancer types.

Informacja